Non–Small Cell Lung Cancer Coverage from Every Angle

Naiyer A. Rizvi, MD, on Immunotherapy: Beyond Checkpoint Inhibition

Posted: Monday, March 20, 2017

Naiyer A. Rizvi, MD, of Columbia University Medical Center, discusses targeting immune suppression in the tumor microenvironment; therapy with engineered T cells, bispecific antibodies, and adoptive T-cell treatment; intramural therapies; and targeting neoantigens.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.